



WEBINAR:
[In Vitro Phenotypic Assays as Predictive Tools to Drive Parkinson's Disease Drug Discovery](#)


Mitochondrial damage as measured by GFP-Parkin localization from predominantly cytoplasmic to punctate mitochondrial localized staining



Design and evaluation of a novel class of small molecules for target degradation



In vivo model validation for pharmacology and efficacy studies (6-OHDA lesion, MPTP, AAV-A53T, A53T transfection model)



PRESS RELEASE:
[Extension of collaboration, May 3, 2018](#)

VIDEO BLOG:
[Spotlight on Parkinson's](#)

SFN 2017 POSTERS:
[Administration of AAV Alpha-synuclein to C57BL6/J and G2019s Mice](#)

[Administration of AAV Alpha-synuclein in SD and G2019S-LRRK2 Rats](#)

[Behavioral Consequences of Administration of AAV Alpha-synuclein to Rat](#)

WEBINARS:
[A Comprehensive Review of Biomarker Endpoints in In Vivo Models of PD](#)

[Using Fine Motor Kinematic and Gait Analysis in In Vivo Pharmacology Studies](#)

[Recent Advances in Preclinical Nuclear Imaging](#)

PUBLICATION

Target Discovery and Validation

Hit ID

Hit-to-Lead


Lead-to-Candidate

Preclinical Development


SFN 2017 POSTERS:
[α-Synuclein Aggregation Assay for PD](#)

POSTER PRESENTATION VIDEO:
[α-Synuclein Aggregation Assay for PD](#)

WEBINAR:
[In Vitro Phenotypic Assays as Predictive Tools to Drive Parkinson's Disease Drug Discovery](#)



Screening of 1,000 computationally selected compounds in 384-well format identified 23 compounds that reduced alpha-synuclein aggregation



Compound 2 selectively reduces alpha-synuclein aggregation